Back

Latest Forum Topics / Biosensors

Post Reply

Is Biosensors a good buy? Post Reply Rate topic
lostbell Member	28-Jun-2011 08:58        lostbell About Contact  Quote this Post! Style: Technical   Mood: Yells: "GOD BLESS EVERYONE!!!"
x 0   x 0  Alert Admin	Interesting and encouraging news..... http://health.asiaone.com/Health/News/Story/A1Story20110627-286115.html
Useful To Me  Not Useful To Me
bishan22 Elite	20-Jun-2011 11:21        bishan22 About Contact  Quote this Post!
x 0   x 0  Alert Admin	strong buy up again, keep it up.  bishan22      ( Date: 14-Jun-2011 09:24) Posted: Up up and away. Good luck. Vested small.  bishan22      ( Date: 13-Jun-2011 10:09) Posted: Strong buying up today.
Useful To Me  Not Useful To Me
jackyt Member	20-Jun-2011 09:44        jackyt About Contact  Quote this Post!
x 0   x 0  Alert Admin	why do u bother anticipating analysts' price targets? as a matter of fact, i think biosensors is still an under-covered stock. DBS assigns a junior, OCBC - retail research lacking quality, CS- non-existent coverage. Nomura is the only one covering the stock well, in fact we should thank them for pushing the stock to where it is now. Unfortunately it appears that they have lost their star analyst, from what i see on the reports i receive.     topdog22 Member Posted: 19-Jun-2011 00:07 x 0 x 0 can anyone help me understand why the price target for BIG has not moved up substantially?  Are these new ratings NOT counting the increased EPS brought about by the acquisition, until the acquisition is complete?  From a simple P.E. perspective the new PT should be in the  $3 range with a 9 or 10 X multiple.  From a combined business basis, BIG is really overpaying or they have decreased the value of BIG.    Any thoughts?
Useful To Me  Not Useful To Me
investor Senior	19-Jun-2011 22:27        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	On further analysis, I think the problem could be that the Fidelity group actually comprises of 14 subsidiaries (as listed in the announcement), and it could be some of these subsidiaries have purchased these shares but did not report to the head office for actual consolidation. Also, If I am not mistaken, the onus is for the shareholders to inform Biosensors about their purchases, as Biosensors will not know which subsidiary has purchased the shares (Correct me if I am wrong). Whatever , It is a good thing that Fidelity group of subsidiaries are interested in Biosensors. Not a call to buy/sell.
Useful To Me  Not Useful To Me
junction Senior	19-Jun-2011 16:57        junction About Contact  Quote this Post!
x 0   x 0  Alert Admin	You and Investor have done good research.  May I suggest you post this to SGX.  I don't quite trust Biosensors management, starting from its Chairman. tiptop123      ( Date: 19-Jun-2011 11:26) Posted:   Wow! They bought another ~13.3M shares @ $1.22-1.29/share in 2 weeks.    15-06-2011 1. Holdings of Substantial Shareholder , including direct and deemed interest :   Direct Deemed No. of shares held before the change 0   107,007,000   As a percentage of issued share capital 0 % 7.97% % No. of shares held after the change 0   108,107,000   As a percentage of issued share capital 0 % 8.05 % tiptop123      ( Date: 03-Jun-2011 23:51) Posted:     They have bought ~13.7M shares since 27 April 11, for $1.28-1.40 a share. Why are they so confident? Do they know something that we don't?   30-05-2011  1. Holdings of Substantial Shareholder , including direct and deemed interest :   Direct Deemed No. of shares held before the change 0   93,520,000   As a percentage of issued share capital 0 % 6.97 % No. of shares held after the change 0   94,764,000   As a percentage of issued share capital 0 % 7.06 %   27-04-2011  1. Holdings of Substantial Shareholder , including direct and deemed interest :   Direct Deemed No. of shares held before the change 0   76,751,000   As a percentage of issued share capital 0 % 5.74 % No. of shares held after the change 0   81,045,000   As a percentage of issued share capital 0 % 6.06 %
Useful To Me  Not Useful To Me
investor Senior	19-Jun-2011 16:07        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	There is something wrong here about the purchases of Biosensors shares by Fidelity. On 30th May, their shareholding was 93.520 million shares, before the new purchase announcement, and after the purchase, the shareholding went to 94.764 million shares. On 15th Jun, when they announced the new purchase, their shareholding has gone up to 107.007 milion shares, before accounting for the new purchase on 15th Jun. In other words, between 31st May to 14th Jun, their shareholding has gone up from 94.764 million shares to 107.007 million shares, without ANY ANNOUNCEMENT to SGX. This clearly violates SGX's rules, where a substantial shareholder (defined as more than 5 %)   has to report change in holdings, probably within a 2 days period (could be 2-3 days, not exactly sure, but definitely not 15 days). Anybody got any ideas, why ? Something strange here. A personal observation. Not a call to buy/sell.
Useful To Me  Not Useful To Me
tiptop123 Member	19-Jun-2011 11:26        tiptop123 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Wow! They bought another ~13.3M shares @ $1.22-1.29/share in 2 weeks.    15-06-2011 1. Holdings of Substantial Shareholder , including direct and deemed interest :   Direct Deemed No. of shares held before the change 0   107,007,000   As a percentage of issued share capital 0 % 7.97% % No. of shares held after the change 0   108,107,000   As a percentage of issued share capital 0 % 8.05 % tiptop123      ( Date: 03-Jun-2011 23:51) Posted:     They have bought ~13.7M shares since 27 April 11, for $1.28-1.40 a share. Why are they so confident? Do they know something that we don't?   30-05-2011  1. Holdings of Substantial Shareholder , including direct and deemed interest :   Direct Deemed No. of shares held before the change 0   93,520,000   As a percentage of issued share capital 0 % 6.97 % No. of shares held after the change 0   94,764,000   As a percentage of issued share capital 0 % 7.06 %   27-04-2011  1. Holdings of Substantial Shareholder , including direct and deemed interest :   Direct Deemed No. of shares held before the change 0   76,751,000   As a percentage of issued share capital 0 % 5.74 % No. of shares held after the change 0   81,045,000   As a percentage of issued share capital 0 % 6.06 %   allright      ( Date: 02-Jun-2011 10:00) Posted: Thats good news as they still believe in this share.
Useful To Me  Not Useful To Me
topdog22 Senior	19-Jun-2011 00:07        topdog22 About Contact  Quote this Post!
x 0   x 0  Alert Admin	can anyone help me understand why the price target for BIG has not moved up substantially?  Are these new ratings NOT counting the increased EPS brought about by the acquisition, until the acquisition is complete?  From a simple P.E. perspective the new PT should be in the  $3 range with a 9 or 10 X multiple.  From a combined business basis, BIG is really overpaying or they have decreased the value of BIG.    Any thoughts?
Useful To Me  Not Useful To Me
investor Senior	18-Jun-2011 14:41        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	The following are excerpts from this week's Edge Magazine on Biosensors. " Chairman, Yoh Chi Lu says that the sharp increase in revenue from the acquisition of JWMS is possible despite growing pressure in the selling price of DES, due to competition. " " The reality is that prices will continue to come down, but volume is expected to continue to increase, he says, " I think that volume will increase MUCH MORE rapidly. " Jack Wang, Co-CEO, says that the company will have a broad range of products to meet demand in China, following the acquisition, including a " WHOLE FAMILY" of DESs. There are so many combination of products that we can pick from. We can use anything we want to attack the China market. He expects overall sales of DESs in China to increase 25 % to 30 % annually in the next couple of yrs." " Biosensors could soon have another product with which to tap the burgeoning China market.. It expects to receive the approval for the bio-matrix, later THIS YEAR or NEXT. " Its hard to predict the exact date, but we can say its COMING." says Wang. Chairman, Lu also say " We are not going to overlook the possibility and upside potential of using Biosensor's platform to distribute to markets outside China, all the products manufactured by Weigao, as well as JWMS, thru a cost-effective approach." Weigao's products include medical consumables, such as syringes, blood bags, as well as orthopaedic materials. For information. Not a call to buy/sell.
Useful To Me  Not Useful To Me
infancybird Senior	17-Jun-2011 21:11        infancybird About Contact  Quote this Post!
x 0   x 0  Alert Admin	On 15-6-2011, one of BIG`s substantial holder Fidelity gp bought 1.1million share in the open market to reach a share holding of 8.05% from 7.6%. Good sign big boy is accumulating BIG shares.     investor      ( Date: 15-Jun-2011 23:03) Posted: The fact that J & J is exiting the DES business, can only be good news for Biosensors as well as the other 3 major players, ie Abbot, Boston Scientific and Medtronics. There should be some spill over effects to Biosensors as its DES was directly compared to the J & J DES, in the Leaders Trial. On top of that, there will be no bio-degradable polymer DES that will come out in the forseeable future, leaving Biosensors as the only one that is commercialised. Not a call to buy/sell.
Useful To Me  Not Useful To Me
investor Senior	15-Jun-2011 23:03        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	The fact that J & J is exiting the DES business, can only be good news for Biosensors as well as the other 3 major players, ie Abbot, Boston Scientific and Medtronics. There should be some spill over effects to Biosensors as its DES was directly compared to the J & J DES, in the Leaders Trial. On top of that, there will be no bio-degradable polymer DES that will come out in the forseeable future, leaving Biosensors as the only one that is commercialised. Not a call to buy/sell.
Useful To Me  Not Useful To Me
JustForFun Member	15-Jun-2011 22:52        JustForFun About Contact  Quote this Post!
x 0   x 0  Alert Admin	Johnson & Johnson's Cordis Corp. unit will exit the drug-eluting stent business to focus on other cardiovascular devices, a move that will result in a $500 million to $600 million second-quarter restructuring charge. " Due to evolving market dynamics in the drug-eluting stent business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market," said Seth Fischer, company group chair and world-wide chairman of Cordis. The company will end its development of the Nevo sirolimus-eluting coronary stent and will stop the manufacture of Cypher and Cypher Select Plus sirolimus-eluting coronary stents by the year end. Cordis will close its Cashel, Ireland, and San German, Puerto Rico, manufacturing facilities and consolidate its research and development teams in Fremont, Calif., resulting in the elimination of 900 to 1,000 positions. The Biosense Webster business will continue to focus on the electrophysiology market while Cordis expands its product portfolio for endovascular and cardiology procedures. These businesses generated 2010 sales of $1.9 billion. Johnson & Johnson reported in April that its first-quarter earnings declined 23% from a year-earlier period that was boosted by a litigation gain while the health-care conglomerate's sales rose 3.5% to $16.17 billion.
Useful To Me  Not Useful To Me
investor Senior	15-Jun-2011 20:15        investor About Contact  Quote this Post!
x 0   x 0  Alert Admin	After the announcement of the acquisition, I observed that there is a tussle between the bulls and the bears, the past 3 days, with the bears selling down the stock, and the bulls coming to support it the last few mins or so before closing bell. It is anybody's guess, where it will go from here, although, I would like to think that the recent low of 1.22 will be supported, and the stock will consolidate in this range for a while. First, the positive - It is probably due to the new shareholders, Hony Capital entering in Oct 2010, and then subsequently, Alantis and the other fund that enabled Biosensors to buy over JWMS. Obviously, they must be confident of the acq going thru. 2ndly, I am sure that going forward, these new shareholders will enable Biosensors to get approval in China, sooner than later. THe 50 % purchase of the JWMS will contribute an additional US$20m or more to their bottom line per yr, Initially, the acq looks dilutive to Biosensors, but if you take away other charges, like depn, etc, the straight thru of US$20m will be slightly accretive to Biosensors, despite the issue of more shares. It is also a fact, that Biosensors paid mkt value for the 50 % stake in JWMS, but on the other hand, the 50 % that they owned will now be marked to the mkt value, and therefore Biosensor's NAV is now much higher, ie at least US$1 billion. GOing forward, the profit contribution from JWMS will continue to grow, probably quite strongly. It will contribute at least US$40m to the bottom line, per yr. Biosensors, now is the 3rd largest player in China, will be a major player in Japan (due to Terumo), and making good inroads into Europe - It is not hard for funds and investors alike to take a fancy to Biosensors. A personal comment. Not a call to buy/sell.
Useful To Me  Not Useful To Me
tiptop123 Member	14-Jun-2011 21:16        tiptop123 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Published June 14, 2011 Biosensors ups revenue growth guidance Top line could go to about US$235-250m, after takeover of China firm By CHEN HUIFEN (SINGAPORE) Heart stent maker Biosensors International Group said that its topline growth for the current financial year is likely to be adjusted upwards to 50-60 per cent, from an earlier guidance of 20-30 per cent, after the completion of its latest acquisition in JW Medical Systems (JWMS). Based on its last reported total revenue of US$156.6 million for the year ended March 31 this year, this could mean a top line of about US$235-250 million for FY2012. This is despite pricing pressure from competition that is lowering the average selling price of drug-eluting stents (DES) worldwide. In a global conference call held last night, chairman Lu Yoh Chie pointed out that the DES market in China - where JWMS has a strong distribution network - has been growing in double-digits for the last few years. And with cardiovascular disease one of the top killers in China, the demand for JWMS' stents could only grow. 'Currently, it is estimated that China's DES market is around US$500 million a year and still growing fast,' said Mr Lu. 'With the commitment by government to invest in the multi-year healthcare reform programme, and recent inclusion of DES treatment as part of the reimbursement programme, we anticipate the demand for DES volume to continue to increase in China. In the foreseeable future, China's DES market could potentially surpass the US's.' Mainboard-listed Biosensors is taking full control of JWMS by acquiring the remaining 50 per cent that it does not own for about $625.4 million. The acquisition will be carried out through a cash payment of $160 million, and a combination of new share issue worth $317.6 million and convertible notes issue worth US$120 million. The acquisition, which was announced on Sunday, is subject to shareholder and regulatory approvals. Expected to be completed in September, it will see the vendor, Shandong Weigao Group Medical Polymer Company (Weigao), owning 16.2 per cent of Biosensors upon completion. And when the notes, due in 2014, are converted to shares, Weigao could potentially own 21.6 per cent of Biosensors then. Investors responded positively to the acquisition by pushing up Biosensors' share price by seven cents, or 6 per cent, to $1.29 yesterday. Volume traded amounted to more than 7.1 million shares. The deal was long in coming, as Biosensors had indicated its intention to buy 100 per cent of JWMS - which is key to the lucrative drug eluting stent market in China - when it made the initial 50 per cent acquisition back in 2007. But the transaction was not able to come into effect due to certain legal issues, according to Jiang Qiang, CFO and head of corporate strategy at Shandong Weigao. Already one of the top three DES firms in China, JWMS sells a proprietary Excel DES which, like Biosensors' flagship BioMatrix product, has a biodegradable polymer coating. With JWMS becoming its wholly owned subsidiary, Biosensors intends to introduce more product lines in China and leverage further the former's distribution network. The group is close to obtaining approval for its BioMatrix in China. As for JWMS, the closer relationship with Biosensors would give it access to new technologies and a platform to penetrate overseas markets, which now account for just 5 per cent of total sales. It intends to market products intended for international markets under Biosensors. The latest move by Biosensors follows a change in shareholding several months ago, which saw the entry of Chinese private equity firm Hony Capital as a substantial investor. Hony Capital had bought the entire stake of founder Mr Lu for 88 cents a share last October.
Useful To Me  Not Useful To Me
allright Senior	14-Jun-2011 10:16        allright About Contact  Quote this Post!
x 0   x 0  Alert Admin	OCBC investment Research   Biosensors International Group: Acquiring remaining 50% stake in JWMS Summary: Biosensors International Group (BIG) has proposed to acquire the remaining 50% stake in JW Medical Systems (JWMS) from Shandong Weigao Group Medical Polymer (Shandong Weigao). The purchase consideration amounts to ~S$625.4m, comprising of (i) a cash payment of S$160m (ii) issuance of 260m new ordinary shares to Shandong Weigao at S$1.2215 per share and (iii) issuance to Shandong Weigao of US$120m principal amount of 4% convertible notes due 2014. Shandong Weigao would own 21.6% of BIG, assuming full conversion of the notes. We view this move positively from a strategic standpoint as BIG would now be able to strengthen its position in the fast growing China DES market. Management estimates that this acquisition would be completed by the later part of the year (assuming shareholder approval is obtained), implying that JWMS is likely to be consolidated from 2H12 onwards. We take into account the dilutive impact caused by the enlarged share base and also update our required return on equity assumption to 9.1%. However, our FCFE model also captures the accretive earnings growth potential of the combined entity. As such, our fair value estimate increases from S$1.55 to S$1.60. Maintain  BUY.
Useful To Me  Not Useful To Me
bishan22 Elite	14-Jun-2011 09:24        bishan22 About Contact  Quote this Post!
x 0   x 0  Alert Admin	Up up and away. Good luck. Vested small.  bishan22      ( Date: 13-Jun-2011 10:09) Posted: Strong buying up today.
Useful To Me  Not Useful To Me
vonntan Senior	13-Jun-2011 23:56        vonntan About Contact  Quote this Post!   Mood:
x 0   x 0  Alert Admin	Biosensors triggered a " One white soldier" candlestick formation today. Looking bullish at the moment but faces immediate resistence from it's 100day MA.If it can overcome that resistence, it could trade higher to test 1.32 (next level of resistence, minor one). MACD looks to be forming a bullish crossover soon. Looking good! http://sgsharemarket.com/home/2011/06/singapore-stock-market-screener-13062011/?=Biosensors
Useful To Me  Not Useful To Me
alexchia01 Elite	13-Jun-2011 22:00        alexchia01 About Contact  Quote this Post! Style: Combined   Mood: Yells: "Catch The Stars And Ride With Them"
x 0   x 0  Alert Admin	You should not see this as stupidity or impatience. Every trader has been through this before. Your Buy last week was based on guessing, you don't know where Biosensors is heading. It can goes either way. If you hold and really made money today, it's not because your trading is good, it's just that you are lucky. For now, you are a bit unlucky, but I don't see this as bad thing. At least we know that Biosensors has a chance of moving into the up trend. If you Buy now, it's based on probability of winning and not based on guessing. However, I'm not Buying Biosensors yet. I want to see more Bullish Signal to confirm the trend change. I want to see Biosensors crosses $1.30 and stay above that price before I would Buy.
Useful To Me  Not Useful To Me
tea444u Master	13-Jun-2011 21:05        tea444u About Contact  Quote this Post!   Mood:
x 0   x 0  Alert Admin	sorry folks if   turned nasty... today feel bad about my stupidity and impatience..no one but me own fault.
Useful To Me  Not Useful To Me
tea444u Master	13-Jun-2011 20:14        tea444u About Contact  Quote this Post!   Mood:
x 0   x 0  Alert Admin	oh boy...sure fall tomorrow. infancybird      ( Date: 13-Jun-2011 18:51) Posted: it is a 50:50 game, up or down, your guess is as good as mine, just like casino game black or red. Since you ask for opinion in this forum, some helpful guy may give you his 50% take on down based on market sentiment, not to realize  there is such good good new for biosensor coming up today and so soon. From hindsight, the share price of BIG was forced down recently to accomodate this transection, now that such obstacle is removed, it will soar soon to much higher level from here. I am very positive about this stock, good to keep for 1 to 2 years for more and better news. tea444u      ( Date: 13-Jun-2011 17:23) Posted: will need therapy now... i think people shoudl not anyhow say...now cannot buy lah this and then...make others lose for nothing...
Useful To Me  Not Useful To Me

                                                         First   < Newer   2961-2980 of 10899   Older>   Last